Beth C. Seidenberg - Jun 8, 2021 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
Director
Signature
/s/ Susan Biglieri, Attorney-in-Fact
Stock symbol
ATRA
Transactions as of
Jun 8, 2021
Transactions value $
$0
Form type
4
Date filed
6/9/2021, 07:16 PM
Previous filing
May 18, 2021
Next filing
Jun 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Award $0 +11K +40.46% $0.00 38.2K Jun 8, 2021 Direct F1
holding ATRA Common Stock 1.82M Jun 8, 2021 See footnote F2
holding ATRA Common Stock 54.4K Jun 8, 2021 See footnote F3
holding ATRA Common Stock 197 Jun 8, 2021 See footnote F4
holding ATRA Common Stock 197 Jun 8, 2021 See footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATRA Non-Qualified Stock Option (Right to Buy) Award $0 +17.5K $0.00 17.5K Jun 8, 2021 Common Stock 17.5K $13.80 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
F2 The shares are directly held by Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV is KPCB XV Associates, LLC ("XV Associates"). The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.
F3 The shares are directly held by KPCB XV Founders Fund, LLC ("KPCB XV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XV FF is XV Associates. The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.
F4 Shares held by the Michael J. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.
F5 Shares held by the Samuel B. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.
F6 The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.